Menu
Menu
This is our data centre where we list selected publications in scientific journals. Links to the publications will be included when allowed by copyright law.
In reviewing these publications, it is helpful to note that our lead drug candidate, NVG-291, is the human analog of NVG-291-R, which has been used in most experiments in rodents. NVG-291-R is also most commonly referred to in the literature as intracellular sigma peptide, or ISP.
Please note that this is not a comprehensive list of all publications related to the identified topics. The same article may be present in our list under multiple headings if it relates to multiple subjects. There may be scientific publications relevant to any of the listed topics that have not been identified by NervGen, or that have not been included in this website.
Functional regeneration beyond the glial scar. Experimental Neurology. Cregg J.M., DePaul M.A., Filous A.R., Lang B.T., Tran A., Silver J., 2014; 253:197–207.
PTPσ Is a Receptor for Chondroitin Sulfate Proteoglycan, an Inhibitor of Neural Regeneration. Science. Shen et al., 2009; 326(5952): 592–596.
Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury. Nature. Lang et al., 2015; 518 404-40.
Modulation of proteoglycan receptor PTPσ enhances MMP-2 activity to promote recovery from multiple sclerosis. Nature Communications. Luo F., Tran A.P., Xin L., et al., 2018; 9(1):1-16.
Recovery after spinal cord injury by modulation of the proteoglycan receptor PTPσ. Experimental Neurology. Rink S., Arnold D., Wöhler A., et al., 2018; 309:148-159.
Inhibition of CSPG receptor PTPσ promotes migration of newly born neuroblasts, axonal sprouting, and recovery from stroke. Luo et al., Cell Reports 2022, Volume 40, Issue 4, 111137.
Regulation of autophagy by inhibitory CSPG interactions with receptor PTPσ and its impact on plasticity and regeneration after spinal cord injury. Experimental Neurology. Tran A.P., Warren P.M., Silver J., 2020; 328:113276.
Recovery of Forearm and Fine Digit Function after Chronic Spinal Cord Injury by Simultaneous Blockade of Inhibitory Matrix CSPG Production and the Receptor PTPσ. Journal of Neurotrauma, August 22, 2023. Milton, Adrianna, Jessica C. F. Kwok, Jacob McClellan, Randall G. Saber, Justin Lathia, Philippa Mary Warren, Daniel J. Silver, and Jerry Silver.
Regeneration beyond the glial scar. Nature Reviews Neuroscience. Silver, J. and Miller, J.H., 2004; 5, 146–156.
Studies on the Development and Behavior of the Dystrophic Growth Cone, the Hallmark of Regeneration Failure, in an In Vitro Model of the Glial Scar and after Spinal Cord Injury. Journal of Neuroscience. Tom V.J., Steinmetz M.P., Miller J.H., Doller C.M., Silver J., 2004; 24(29):6531-6539.
The role of extracellular matrix in CNS regeneration. Current Opinion in Neurobiology. Busch, S. A., Silver, J., 2007; 17, 120–127.
New Insights into Glial Scar Formation after Spinal Cord Injury. Cell and Tissue Research, June 2, 2021. Tran, Amanda Phuong, Philippa Mary Warren, and Jerry Silver.
Enhanced regeneration and functional recovery after spinal root avulsion by manipulation of the proteoglycan receptor PTPσ. Scientific Reports. Li H., Wong C., Li W., et al., 2015; 5(1):1-14.
Rapid and robust restoration of breathing long after spinal cord injury. Nature Communications. Warren et al., 2018; 9:4843.
Automated Gait Analysis Detects Improvements after Intracellular σ Peptide Administration in a Rat Hemisection Model of Spinal Cord Injury. Annals of Biomedical Engineering. Ham T.R., Farrag M., Soltisz A.M., Lakes E.H., Allen K.D., Leipzig N.D., 2019; 47(3):744-753.
Subcutaneous priming of protein-functionalized chitosan scaffolds improves function following spinal cord injury. Materials Science and Engineering: C. Ham T.R., Pukale D.D., Hamrangsekachaee M., Leipzig N.D., 2020; 110:110656.
Recovery of Forearm and Fine Digit Function after Chronic Spinal Cord Injury by Simultaneous Blockade of Inhibitory Matrix CSPG Production and the Receptor PTPσ. Journal of Neurotrauma, August 22, 2023. Milton, Adrianna, Jessica C. F. Kwok, Jacob McClellan, Randall G. Saber, Justin Lathia, Philippa Mary Warren, Daniel J. Silver, and Jerry Silver.
Inhibition of CSPG receptor PTPσ promotes migration of newly born neuroblasts, axonal sprouting, and recovery from stroke. Cell Reports 2022, Volume 40, Issue 4, 111137. Luo et al.
Modulation of the Proteoglycan Receptor PTPσ Promotes White Matter Integrity and Functional Recovery after Intracerebral Hemorrhage Stroke in Mice. Journal of Neuroinflammation 19, no. 1 (August 18, 2022): 207. Yao, Min, Jie Fang, Jiewei Li, Anson Cho Kiu Ng, Jiaxin Liu, Gilberto Ka Kit Leung, Fanglai Song, Jian Zhang, and Chunqi Chang.
Modulation of proteoglycan receptor PTPσ enhances MMP-2 activity to promote recovery from multiple sclerosis. Nature Communications. Luo F., Tran A.P., Xin L., et al., 2018; 9(1):1-16.
Modulating proteoglycan receptor PTPσ using intracellular sigma peptide improves remyelination and functional recovery in mice with demyelinated optic chiasm. Molecular and Cellular Neuroscience. Niknam P., Raoufy M.R., Fathollahi Y., Javan M., 2019; 99:103391.
LAR and PTPσ receptors are negative regulators of oligodendrogenesis and oligodendrocyte integrity in spinal cord injury. Glia. Dyck S., Kataria H., Akbari‐Kelachayeh K., Silver J., Karimi‐Abdolrezaee S., 2018; 67(1):125-145.
Alzheimer’s disease pathogenesis is dependent on neuronal receptor PTPσ. bioRxiv. Gu Y., Shu Y., Corona A., et al., 2016; 079806.
Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. Experimental Neurology. Yang S., Cacquevel M., Saksida L.M., et al., 2015; 265:48-58.
Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration. Neurobiology of Aging. Yang S., Hilton S., Alves J.N., et al., 2017; 59:197-209.
Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease. Acta Neuropathologica Communications. Végh M.J., Heldring C.M., Kamphuis W., et al., 2014; 11.
Astrocyte-Secreted Glypican 4 Regulates Release of Neuronal Pentraxin 1 from Axons to Induce Functional Synapse Formation. Neuron. Farhy-Tselnicker I., van Casteren A.C.M., Lee A., Chang V.T., Aricescu A.R., Allen N.J., 2017; 96(2):428-445.e13.
Modulation of Receptor Protein Tyrosine Phosphatase Sigma Increases Chondroitin Sulfate Proteoglycan Degradation through Cathepsin B Secretion to Enhance Axon Outgrowth. Journal of Neuroscience. Tran A.P., Sundar S., Yu M., Lang B.T., Silver J., 2018; 38(23):5399–5414.
Glycan sulfation patterns define autophagy flux at axon tip via PTPRσ-cortactin axis. Nature Chemical Biology. Sakamoto K., Ozaki T., Ko Y-C., et al., 2019; 15(7):699-709.
Receptor protein tyrosine phosphatases control Purkinje neuron firing. Journal Cell Cycle. Brown A.S., Meera P., Quinones G., et al., 2020; 19(2):153-159.
Regulation of autophagy by inhibitory CSPG interactions with receptor PTPσ and its impact on plasticity and regeneration after spinal cord injury. Experimental Neurology. Tran A.P., Warren P.M., Silver J., 2020; 328:113276.
Modulation of proteoglycan receptor PTPσ enhances MMP-2 activity to promote recovery from multiple sclerosis. Nature Communications, Luo, F et al., (2018), 9, 1-16.
Modulation of proteoglycan receptor regulates RhoA/CRMP2 pathways and promotes axonal myelination. Neurosci Lett. Yao M, Fang J, Tao W, Feng G, Wei M, Gao Y, Xin W, Li Y, Du S. (2021), 760:136079.
Targeting protein tyrosine phosphatase σ after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nature Communications. Gardner R.T., Wang L., Lang B.T., et al., 2015; 6(1):6235.
Disrupting protein tyrosine phosphatase σ does not prevent sympathetic axonal dieback following myocardial infarction. Experimental Neurology. Johnsen D., Olivas A., Lang B., Silver J., Habecker B., 2016; 276:1–4.
Correlation between the High-Frequency Content of the QRS on Murine Surface Electrocardiogram and the Sympathetic Nerves Density in Left Ventricle after Myocardial Infarction: Experimental Study. Journal of Electrocardiology. Sedaghat G., Gardner R.T., Kabir M.M., Ghafoori E., Habecker B.A., Tereshchenko L.G., 2017; 50(3):323-331.
ISP and PAP4 peptides promote motor functional recovery after peripheral nerve injury. Neural regeneration research. Lv, Shi-Qin, and Wutian Wu. Vol. 16,8 (2021): 1598-1605. doi:10.4103/1673-5374.294565.
Modulation of proteoglycan receptor regulates RhoA/CRMP2 pathways and promotes axonal myelination. Neurosci Lett. Yao M, Fang J, Tao W, Feng G, Wei M, Gao Y, Xin W, Li Y, Du S. 2021 Aug 24;760:136079. doi: 10.1016/j.neulet.2021.136079. Epub 2021 Jun 21. PMID: 34166723.
Inhibition of the Proteoglycan Receptor PTPσ Promotes Functional Recovery on a Rodent Model of Preterm Hypoxic-Ischemic Brain Injury. Experimental Neurology, October 6, 2023, 114564.
Chondroitinase ABC digestion of the perineuronal net promotes functional collateral sprouting in the cuneate nucleus after cervical spinal cord injury. Journal of Neuroscience. Massey, J. M. et al., 2006; 26, 4406–4414.
Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury. Experimental Neurology. Andrews, E.M., Richards, R.J., Yin, F.Q., Viapiano, M.S., Jakeman, L.B., 2012; 235, 174–187.
Quantitative changes in perineuronal nets in development and posttraumatic condition. Journal of Molecular Histology. Lipachev, N. et al., 2019; 50, 203–216.
Reactivation of ocular dominance plasticity in the adult visual cortex. Science. Pizzorusso, T. et al., 2002; 298, 1248–1251.
Chondroitinase ABC promotes selective reactivation of somatosensory cortex in squirrel monkeys after a cervical dorsal column lesion. Proceedings of the National Academy of Sciences. Bowes C., Massey J.M., Burish M., Cerkevich C.M., Kaas J.H., 2012; 109 (7) 2595-2600.
Click here to view scientific presentations by NervGen
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com